ArticleBioengineering (Basel, Switzerland)2025
Advanced Silicon Modeling of Native Mitral Valve Physiology: A New Standard for Device and Procedure Testing.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitral valve regurgitation is among the most prevalent valvular heart diseases and increases with age. Percutaneous therapy has emerged for the management of mitral regurgitation in high surgical risk patients. However, the long-term consequences of these interventions are still not fully understood due to their novelty and the difficulty of developing a strategy specific to the patient's anatomy and/or pathology. To optimize these outcomes, an in vitro patient-specific approach could provide important insights for the most suitable strategy to use according to the patient profile. To ensure the reliability of this in vitro approach, the aim of this study was to reproduce the physiological behavior of the healthy native mitral valve for future applications. To do so, different silicon combinations reproducing the physiological anatomy of a healthy mitral valve were developed and tested under physiological hemodynamic conditions in a cardiac simulator. The hemodynamic and biomechanical behaviors of each mitral valve model were analyzed and compared to the physiological values provided in the literature. This study identified EcoFlex 00-50 and DragonSkin 10 (Smooth-On Inc., Easton, PA, USA) as the optimal silicon combination resulting in physiological strain values and hemodynamic parameters. These findings could be useful for future patient-specific applications, helping in the optimization of percutaneous mitral valve therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.